CPTX2309

Phase 1Small molecule

CCapstan Therapeutics

CPTX2309 is one of 33 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisRecruiting

Rheumatoid ArthritisPhase 1

Recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Disalcid

JJoslin Diabetes Center

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Rheumatoid Arthritis

NCT06917742

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A First-in-Human, Phase 1, Open-Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CPTX2309 by Intravenous Administration in Healthy Volunteers and Subjects With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Recruiting·CCapstan Therapeutics·Phase 1·NCT06917742·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CPTX2309. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CPTX2309 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CPTX2309. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Capstan Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCapstan Therapeutics

CPTX2309

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News